1eby
From Proteopedia
| Line 24: | Line 24: | ||
==Reference== | ==Reference== | ||
Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors., Andersson HO, Fridborg K, Lowgren S, Alterman M, Muhlman A, Bjorsne M, Garg N, Kvarnstrom I, Schaal W, Classon B, Karlen A, Danielsson UH, Ahlsen G, Nillroth U, Vrang L, Oberg B, Samuelsson B, Hallberg A, Unge T, Eur J Biochem. 2003 Apr;270(8):1746-58. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12694187 12694187] | Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors., Andersson HO, Fridborg K, Lowgren S, Alterman M, Muhlman A, Bjorsne M, Garg N, Kvarnstrom I, Schaal W, Classon B, Karlen A, Danielsson UH, Ahlsen G, Nillroth U, Vrang L, Oberg B, Samuelsson B, Hallberg A, Unge T, Eur J Biochem. 2003 Apr;270(8):1746-58. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12694187 12694187] | ||
| + | |||
| + | Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy., Lindberg J, Pyring D, Lowgren S, Rosenquist A, Zuccarello G, Kvarnstrom I, Zhang H, Vrang L, Classon B, Hallberg A, Samuelsson B, Unge T, Eur J Biochem. 2004 Nov;271(22):4594-602. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/15560801 15560801] | ||
[[Category: HIV-1 retropepsin]] | [[Category: HIV-1 retropepsin]] | ||
[[Category: Human immunodeficiency virus 1]] | [[Category: Human immunodeficiency virus 1]] | ||
| Line 31: | Line 33: | ||
[[Category: Protein-inhibitor complex]] | [[Category: Protein-inhibitor complex]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 10:23:11 2008'' |
Revision as of 07:23, 28 July 2008
HIV-1 protease in complex with the inhibitor BEA369
Template:ABSTRACT PUBMED 12694187
About this Structure
1EBY is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.
Reference
Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors., Andersson HO, Fridborg K, Lowgren S, Alterman M, Muhlman A, Bjorsne M, Garg N, Kvarnstrom I, Schaal W, Classon B, Karlen A, Danielsson UH, Ahlsen G, Nillroth U, Vrang L, Oberg B, Samuelsson B, Hallberg A, Unge T, Eur J Biochem. 2003 Apr;270(8):1746-58. PMID:12694187
Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy., Lindberg J, Pyring D, Lowgren S, Rosenquist A, Zuccarello G, Kvarnstrom I, Zhang H, Vrang L, Classon B, Hallberg A, Samuelsson B, Unge T, Eur J Biochem. 2004 Nov;271(22):4594-602. PMID:15560801
Page seeded by OCA on Mon Jul 28 10:23:11 2008
